Stock Details
MDT is Medtronic plc's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 107.30$. Average daily volumn in 3 months 5.79M. Market cap 137.55B



Stock symbol : MDT. Exchange : NYSE. Currency : USD
Lastest price : 102.53$. Total volume : 5.32M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Medtronic plc (MDT)
Last Price
102.53$
Change
-0.22
Volume
5.32M

Previous Close102.75
Open103.53
Day Range100.42-103.53
Bid102.40 x 1.2k
Ask103.30 x 800
Volume5.32M
Average Volume5.79M
Market Cap137.55B
Beta0.75
52 Week Range98.38-135.89
Trailing P/E28.25
Foward P/E17.62
Dividend (Yield %)2.45%
Ex-Dividend Date2022-03-24



Financial Details


According to Medtronic plc's financial reports the company's revenue in 2021 were 30.12B an increase( +7.14%) over the years 2020 revenue that were of 28.91B. In 2021 the company's total earnings were 3.61B while total earnings in 2020 were 4.79B(-25%).


Loading ...



Organization

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor sys... tems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Market Cap:
137.55B
Revenue:
30.12B
Total Assets:
93.08B
Total Cash:
3.59B


News about "Medtronic plc"

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Source from : Yahoo News Singapore - 9 hours ago

DUBLIN, May 19, 2022 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 ...See details»


Medtronic plc (MDT): A Sitting Duck With More Than -46.48% Upside

Source from : stocksregister - 17 hours ago

Medtronic plc (NYSE:MDT) at last check was buoying at $101.72 on Friday, May 20 with a fall of -1.00% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»


Medtronic plc [MDT] Stock trading around $103.57 per share: Whatโ€™s Next?

Source from : dbtnews - 1 days ago

Medtronic plc loss -2.53% or -2.69 points to... Medtronic plc [NYSE: MDT] loss -2.53% or -2.69 points to close at $103.57 with a heavy trading volume of 4121151 shares. The company report on May 18, ...See details»


Medtronic touts data for Resolute Onyx, Picardia data indicates TAVR shortcut

Source from : BioWorld - 10 hours ago

Following last weekโ€™s FDA approval of its Onyx Frontier drug eluting stent (DES), Medtronic plc released results at EuroPCR from a real-world, multicenter prospective study using its Resolute Onyx ...See details»


citigroup-cuts-medtronic-nysemdt-price-target-to-12000-image

Citigroup Cuts Medtronic (NYSE:MDT) Price Target to $120.00

Source from : ETF Daily News - 3 days ago

80.23% of the stock is currently owned by institutional investors. About Medtronic (Get Rating) Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals ...See details»


Gear up for the change! Medtronic plc (MDT) has hit the volume of 1073642

Source from : investchronicle - 2 days ago

Medtronic plc (MDT) is priced at $104.82 after the most recent trading session. At the very opening of the session, the stock price was $105.27 and reached a high price of $106.33, prior to closing ...See details»


surgical-sutures-market-2029-impressively-grow-in-future-by-top-companies-analysis-medtronic-plc-bbraun-melsungen-ag-ethicon-image

Surgical Sutures Market 2029 Impressively Grow in Future by Top Companies Analysis: Medtronic plc, B.Braun Melsungen AG, Ethicon

Source from : Digital Journal - 2 days ago

Some of the key players in the global surgical suture market include Medtronic plc, B.Braun Melsungen AG, Ethicon, Inc., Smith & Nephew, Boston Scientific Corporation, international Farmacรฉutica, ...See details»


medtronic-plc-announces-fda-approval-for-onyx-frontier-des-quick-facts-image

Medtronic Plc Announces FDA Approval For Onyx Frontier DES - Quick Facts

Source from : Nasdaq - 7 days ago

Medtronic plc (MDT) has received FDA approval for the Onyx Frontier drug-eluting stent for the treatment of patients with coronary artery disease, which is caused by plaque buildup on the inside of ...See details»


Medtronic completes acquisition of Intersect ENT

Source from : YAHOO!Finance - 7 days ago

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT, expanding the company's comprehensive ear, nose, and throat ...See details»


Medtronic receives FDA approval for latest generation drug-eluting coronary stent system

Source from : Associated Press - 7 days ago

The Onyx Frontierโ„ข drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyxโ„ข drug-eluting stent.See details»


ventilators-market-to-see-booming-growth-by-2026-becton-philips-healthcare-resmed-inc-medtronic-image

Ventilators Market to See Booming Growth by 2026 | Becton, Philips Healthcare, ResMed Inc., Medtronic

Source from : Digital Journal - 1 days ago

CMI has recently updated the the โ€œVentilators Marketโ€ which aims to provide a thorough examination of the factors influencing global business introduction ...See details»


medtronic-offers-new-data-backing-rdn-system-for-blood-pressure-control-image

Medtronic offers new data backing RDN system for blood pressure control

Source from : BioWorld - 4 days ago

Medtronic plc has presented three-year data on its global, multicenter, blinded, randomized and sham-controlled renal denervation (RDN) clinical program Spyral HTN-ON MED during the late-breaking ...See details»


EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Source from : YAHOO!Finance - 3 days ago

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyralโ„ข Renal Denervation ...See details»


ftc-says-medtronic-must-divest-subsidiary-of-device-maker-it-wants-to-acquire-image

FTC says Medtronic must divest subsidiary of device maker it wants to acquire

Source from : StarTribune - 8 days ago

Medical device manufacturer is trying to buy Intersect NET Inc., a maker of sinus implants, in a $936.2 million deal.See details»